Metascreen

Last updated
Metascreen
ProductsMetascreen metabolic screening test
OwnerCordlife Group Limited
Website http://www.metascreen.org

Metascreen is an advanced non-invasive metabolic screening test distributed by Cordlife Group Limited ("Cordlife"). It can detect as many as 110 inborn errors of metabolism ("IEMs", or metabolic disorders) from a urine specimen. Cordlife owns the brand name and trademark, "Metascreen".

Contents

History

Metascreen, as a newborn metabolic screening test, was first launched by Cordlife in India in October 2013. [1] Since April 2014, Metascreen became available also in Hong Kong and the Philippines through Cordlife for parents looking for more comprehensive screening of metabolic disorders for their children. As a newborn suffering from certain metabolic disorder, such as isovaleric acidemia, may appear asymptomatic in the first few days or even weeks of life, early detection and treatment is key in preventing irreversible lifelong complications, such as physical disability or mental retardation.[ citation needed ]

Technology

Unlike the conventional dried blood spot test for newborn screening that involves a painful heel prick, Metascreen uses urine specimen, collected without harm or discomfort to the newborn, to detect as many as 110 metabolic disorders. The urine specimen is collected on a filter paper, which is then air-dried and sent to the laboratory for analysis using a gas chromatography-mass spectrometry instrument ("GC-MS"). GC-MS is a FDA approved method for urinary analyte detection, a gold standard for lipids, drug metabolites and environmental analysis. [2]

Many of the IEMs that are classified as "organic acidemia", in which organic acids accumulate in the urine of newborns with these disorders, [3] are easily and accurately picked up by GC-MS.. The GC-MS platform is recommended by the American College of Medical Genetics for the detection of organic and amino acidemias through the urine. [4] Furthermore, the platform has also been shown to be reliable in detecting other types of IEMs, such as sugar metabolism disorders and fatty acid oxidation disorders. [3] [5] Indeed, GC-MS analysis is increasingly becoming a common way to diagnose IEMs for earlier intervention and treatment, resulting in a better outcome and quality of life.[ citation needed ]

Use of urine as a diagnostic biofluid

As a major organ for excretion, the kidney removes waste materials and chemicals from the body, [6] such as increased concentrations of intermediary metabolites of a particular pathway, making urine (the waste product from the kidney) particularly useful for medical diagnostics. The key advantages of using urine as a biofluid are: (1) its sterility; (2) accessibility and non-invasive method of collection; and (3) it being largely free from interfering proteins or lipids. [7]

Although the human urine metabolome is a subset of the human serum metabolome, more than 484 compounds identified in urine by Bouatra et al. (either experimentally or via literature review) were not previously reported to be in blood. [7] The same group hypothesised that this is because the kidneys do an extraordinary job of removing and/or concentrating certain metabolites from the blood, hence, compounds far below the limit of detection in blood (using today’s instrumentation) are well above the detection limit in urine. [7] This difference, combined with the ability of the kidneys to handle abnormally high or abnormally low concentrations of metabolites, makes urine a particularly useful biofluid for medical diagnostics. [7] In fact, urinary metabolites have been used to characterize nearly 220 diseases. [7]

Controversies

Cordlife announced in October 2013 that Cordlife India has introduced Metascreen service through a strategic collaboration with Navigene Genetic Science, a genetic diagnostic and research company. [8] In 2014, Navigene was embroiled in a controversy where its founders were accused of data and scientific research theft and fined for INR 3 Million by the Adjudicating Authority of the Department of Information Technology, Government of India. [9] [10] Navigene rejected all allegations [11] and has filed a writ petition (No. WP/3291/2014) with the High Court of Mumbai to challenge and squash the order.

Related Research Articles

<span class="mw-page-title-main">Methylmalonic acidemia</span> Medical condition

Methylmalonic acidemia, also called methylmalonic aciduria, is an autosomal recessive metabolic disorder that disrupts normal amino acid metabolism. It is a classical type of organic acidemia. The result of this condition is the inability to properly digest specific fats and proteins, which in turn leads to a buildup of a toxic level of methylmalonic acid in the blood.

<span class="mw-page-title-main">Hyperammonemia</span> Medical condition

Hyperammonemia is a metabolic disturbance characterised by an excess of ammonia in the blood. It is a dangerous condition that may lead to brain injury and death. It may be primary or secondary.

<span class="mw-page-title-main">Medium-chain acyl-coenzyme A dehydrogenase deficiency</span> Medical condition

Medium-chain acyl-CoA dehydrogenase deficiency is a disorder of fatty acid oxidation that impairs the body's ability to break down medium-chain fatty acids into acetyl-CoA. The disorder is characterized by hypoglycemia and sudden death without timely intervention, most often brought on by periods of fasting or vomiting.

<span class="mw-page-title-main">Newborn screening</span> Practice of testing infants for diseases

Newborn screening (NBS) is a public health program of screening in infants shortly after birth for conditions that are treatable, but not clinically evident in the newborn period. The goal is to identify infants at risk for these conditions early enough to confirm the diagnosis and provide intervention that will alter the clinical course of the disease and prevent or ameliorate the clinical manifestations. NBS started with the discovery that the amino acid disorder phenylketonuria (PKU) could be treated by dietary adjustment, and that early intervention was required for the best outcome. Infants with PKU appear normal at birth, but are unable to metabolize the essential amino acid phenylalanine, resulting in irreversible intellectual disability. In the 1960s, Robert Guthrie developed a simple method using a bacterial inhibition assay that could detect high levels of phenylalanine in blood shortly after a baby was born. Guthrie also pioneered the collection of blood on filter paper which could be easily transported, recognizing the need for a simple system if the screening was going to be done on a large scale. Newborn screening around the world is still done using similar filter paper. NBS was first introduced as a public health program in the United States in the early 1960s, and has expanded to countries around the world.

<span class="mw-page-title-main">Gas chromatography–mass spectrometry</span> Analytical method

Gas chromatography–mass spectrometry (GC-MS) is an analytical method that combines the features of gas-chromatography and mass spectrometry to identify different substances within a test sample. Applications of GC-MS include drug detection, fire investigation, environmental analysis, explosives investigation, and identification of unknown samples, including that of material samples obtained from planet Mars during probe missions as early as the 1970s. GC-MS can also be used in airport security to detect substances in luggage or on human beings. Additionally, it can identify trace elements in materials that were previously thought to have disintegrated beyond identification. Like liquid chromatography–mass spectrometry, it allows analysis and detection even of tiny amounts of a substance.

<span class="mw-page-title-main">Metabolomics</span> Scientific study of chemical processes involving metabolites

Metabolomics is the scientific study of chemical processes involving metabolites, the small molecule substrates, intermediates, and products of cell metabolism. Specifically, metabolomics is the "systematic study of the unique chemical fingerprints that specific cellular processes leave behind", the study of their small-molecule metabolite profiles. The metabolome represents the complete set of metabolites in a biological cell, tissue, organ, or organism, which are the end products of cellular processes. Messenger RNA (mRNA), gene expression data, and proteomic analyses reveal the set of gene products being produced in the cell, data that represents one aspect of cellular function. Conversely, metabolic profiling can give an instantaneous snapshot of the physiology of that cell, and thus, metabolomics provides a direct "functional readout of the physiological state" of an organism. There are indeed quantifiable correlations between the metabolome and the other cellular ensembles, which can be used to predict metabolite abundances in biological samples from, for example mRNA abundances. One of the ultimate challenges of systems biology is to integrate metabolomics with all other -omics information to provide a better understanding of cellular biology.

<span class="mw-page-title-main">Metabolome</span>

The metabolome refers to the complete set of small-molecule chemicals found within a biological sample. The biological sample can be a cell, a cellular organelle, an organ, a tissue, a tissue extract, a biofluid or an entire organism. The small molecule chemicals found in a given metabolome may include both endogenous metabolites that are naturally produced by an organism as well as exogenous chemicals that are not naturally produced by an organism.

Inborn errors of metabolism form a large class of genetic diseases involving congenital disorders of enzyme activities. The majority are due to defects of single genes that code for enzymes that facilitate conversion of various substances (substrates) into others (products). In most of the disorders, problems arise due to accumulation of substances which are toxic or interfere with normal function, or due to the effects of reduced ability to synthesize essential compounds. Inborn errors of metabolism are now often referred to as congenital metabolic diseases or inherited metabolic disorders. To this concept it's possible to include the new term of Enzymopathy. This term was created following the study of Biodynamic Enzymology, a science based on the study of the enzymes and their derivated products. Finally, inborn errors of metabolism were studied for the first time by British physician Archibald Garrod (1857–1936), in 1908. He is known for work that prefigured the "one gene-one enzyme" hypothesis, based on his studies on the nature and inheritance of alkaptonuria. His seminal text, Inborn Errors of Metabolism, was published in 1923.

<span class="mw-page-title-main">Isovaleric acidemia</span> Medical condition disrupting normal metabolism

Isovaleric acidemia is a rare autosomal recessive metabolic disorder which disrupts or prevents normal metabolism of the branched-chain amino acid leucine. It is a classical type of organic acidemia.

<span class="mw-page-title-main">Maple syrup urine disease</span> Autosomal recessive metabolic disorder

Maple syrup urine disease (MSUD) is an autosomal recessive metabolic disorder affecting branched-chain amino acids. It is one type of organic acidemia. The condition gets its name from the distinctive sweet odor of affected infants' urine and earwax, particularly prior to diagnosis and during times of acute illness.

<span class="mw-page-title-main">Tyrosinemia</span> Medical condition

Tyrosinemia or tyrosinaemia is an error of metabolism, usually inborn, in which the body cannot effectively break down the amino acid tyrosine. Symptoms of untreated tyrosinemia include liver and kidney disturbances. Without treatment, tyrosinemia leads to liver failure. Today, tyrosinemia is increasingly detected on newborn screening tests before any symptoms appear. With early and lifelong management involving a low-protein diet, special protein formula, and sometimes medication, people with tyrosinemia develop normally, are healthy, and live normal lives.

<span class="mw-page-title-main">Medical genetics</span> Medicine focused on hereditary disorders

Medical genetics is the branch of medicine that involves the diagnosis and management of hereditary disorders. Medical genetics differs from human genetics in that human genetics is a field of scientific research that may or may not apply to medicine, while medical genetics refers to the application of genetics to medical care. For example, research on the causes and inheritance of genetic disorders would be considered within both human genetics and medical genetics, while the diagnosis, management, and counselling people with genetic disorders would be considered part of medical genetics.

<span class="mw-page-title-main">Histidinemia</span> Histidine metabolism disease that involves a deficiency of the enzyme histidase

Histidinemia is a rare autosomal recessive metabolic disorder caused by a deficiency of the enzyme histidase. Histidase is needed for the metabolism of the amino acid histidine. Although originally thought to be linked to multiple developmental disorders histidinemia is now accepted as a relatively benign disorder, leading to a reduction in the prevalence of neonatal screening procedures.

<span class="mw-page-title-main">Urine organic acids</span>

Urine organic acids is a medical diagnostic test that measures organic acid metabolites in the urine. The metabolites can come from host cells or from flora. The test can be used to exclude the possibility that a person has an inborn error of metabolism, usually one of the organic acidemias. It is also used to look for problems with nutrition or evidence of certain infections or bacterial overgrowth. The usual method of analysis is tandem mass spectrometry.

<span class="mw-page-title-main">Guanidinoacetate methyltransferase deficiency</span> Medical condition

Guanidinoacetate methyltransferase deficiency is an autosomal recessive cerebral creatine deficiency that primarily affects the nervous system and muscles. It is the first described disorder of creatine metabolism, and results from deficient activity of guanidinoacetate methyltransferase, an enzyme involved in the synthesis of creatine. Clinically, affected individuals often present with hypotonia, seizures and developmental delay. Diagnosis can be suspected on clinical findings, and confirmed by specific biochemical tests, brain magnetic resonance spectroscopy, or genetic testing. Biallelic pathogenic variants in GAMT are the underlying cause of the disorder. After GAMT deficiency is diagnosed, it can be treated by dietary adjustments, including supplementation with creatine. Treatment is highly effective if started early in life. If treatment is started late, it cannot reverse brain damage which has already taken place.

<span class="mw-page-title-main">Phenylacetylglutamine</span> Chemical compound

Phenylacetylglutamine is a product formed by the conjugation of phenylacetate and glutamine. It is a common metabolite that occurs naturally in human urine.

Organic acidemia, is a term used to classify a group of metabolic disorders which disrupt normal amino acid metabolism, particularly branched-chain amino acids, causing a buildup of acids which are usually not present.

Pharmacometabolomics, also known as pharmacometabonomics, is a field which stems from metabolomics, the quantification and analysis of metabolites produced by the body. It refers to the direct measurement of metabolites in an individual's bodily fluids, in order to predict or evaluate the metabolism of pharmaceutical compounds, and to better understand the pharmacokinetic profile of a drug. Alternatively, pharmacometabolomics can be applied to measure metabolite levels following the administration of a pharmaceutical compound, in order to monitor the effects of the compound on certain metabolic pathways(pharmacodynamics). This provides detailed mapping of drug effects on metabolism and the pathways that are implicated in mechanism of variation of response to treatment. In addition, the metabolic profile of an individual at baseline (metabotype) provides information about how individuals respond to treatment and highlights heterogeneity within a disease state. All three approaches require the quantification of metabolites found in bodily fluids and tissue, such as blood or urine, and can be used in the assessment of pharmaceutical treatment options for numerous disease states.

Combined malonic and methylmalonic aciduria (CMAMMA), also called combined malonic and methylmalonic acidemia is an inherited metabolic disease characterized by elevated levels of malonic acid and methylmalonic acid. Some researchers have hypothesized that CMAMMA might be one of the most common forms of methylmalonic acidemia, and possibly one of the most common inborn errors of metabolism. Due to being infrequently diagnosed, it most often goes undetected.

References

  1. "Cordlife launches MetaScreen Metabolic Screening Service".
  2. "Colin F. Poole, Gas Chromatography, Elsevier 2012".{{cite journal}}: Cite journal requires |journal= (help)
  3. 1 2 "Kuhara, 2001. Diagnosis of inborn errors of metabolism using filter paper urine, urease treatment, isotope dilution and gas chromatography-mass spectrometry. J. Chromatogr. B. 758 (2001): 3-25" (PDF).{{cite journal}}: Cite journal requires |journal= (help)
  4. "American College of Medical Geneticists, Standards and Guidelines for Clinical Genetics Laboratory".{{cite journal}}: Cite journal requires |journal= (help)
  5. "Shoemaker, J. D., 2010. One-step metabolomics: carbohydrates, organic and amino acids quantified in a single procedure, J Vis Exp 40".{{cite journal}}: Cite journal requires |journal= (help)
  6. "WedMD Information and Resources, Your kidneys and how they work". Archived from the original on 2014-09-02.
  7. 1 2 3 4 5 "Bouatra S, Aziat F, Mandal R, Guo AC, Wilson MR, et al. (2013) The Human Urine Metabolome. PLoS ONE 8(9): e73076".{{cite journal}}: Cite journal requires |journal= (help)
  8. http://cordlife.listedcompany.com/newsroom/20131010_073220_P8A_B592E3C2C146005048257BFF0037D404.1.pdf [ bare URL PDF ]
  9. "Statement of Cases - Directorate of Information Technology, Government of Maharashtra, India". Archived from the original on 2014-11-12. Retrieved 2014-11-12.
  10. "Grammatical error nails copycat genetic research firm". 11 March 2014.
  11. "Firm slapped Rs 30 lakh fine for data theft". 25 January 2014.